TISIDB

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Multi-pass membrane protein
Domain	PF00083 Sugar (and other) transporter
Function	Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.

> Gene Ontology [ TOP ]
Biological Process	GO:0001894 tissue homeostasis GO:0006577 amino-acid betaine metabolic process GO:0006814 sodium ion transport GO:0006855 drug transmembrane transport GO:0007586 digestion GO:0009372 quorum sensing GO:0009437 carnitine metabolic process GO:0010669 epithelial structure maintenance GO:0015672 monovalent inorganic cation transport GO:0015695 organic cation transport GO:0015697 quaternary ammonium group transport GO:0015838 amino-acid betaine transport GO:0015879 carnitine transport GO:0015893 drug transport GO:0022600 digestive system process GO:0030277 maintenance of gastrointestinal epithelium GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0042493 response to drug GO:0044057 regulation of system process GO:0044058 regulation of digestive system process GO:0048871 multicellular organismal homeostasis GO:0048872 homeostasis of number of cells GO:0048874 homeostasis of number of cells in a free-living population GO:0051701 interaction with host GO:0052097 interspecies quorum sensing GO:0052106 quorum sensing involved in interaction with host GO:0060249 anatomical structure homeostasis GO:0060456 positive regulation of digestive system process GO:0060729 intestinal epithelial structure maintenance GO:0060730 regulation of intestinal epithelial structure maintenance GO:0060731 positive regulation of intestinal epithelial structure maintenance GO:0070715 sodium-dependent organic cation transport GO:1902603 carnitine transmembrane transport
Molecular Function	GO:0015101 organic cation transmembrane transporter activity GO:0015199 amino-acid betaine transmembrane transporter activity GO:0015226 carnitine transmembrane transporter activity GO:0015238 drug transmembrane transporter activity GO:0015291 secondary active transmembrane transporter activity GO:0015293 symporter activity GO:0015297 antiporter activity GO:0015298 solute:cation antiporter activity GO:0015491 cation:cation antiporter activity GO:0015651 quaternary ammonium group transmembrane transporter activity GO:0022804 active transmembrane transporter activity GO:0030165 PDZ domain binding GO:0072349 modified amino acid transmembrane transporter activity GO:0090484 drug transporter activity GO:0099516 ion antiporter activity
Cellular Component	GO:0005903 brush border GO:0016324 apical plasma membrane GO:0031253 cell projection membrane GO:0031526 brush border membrane GO:0045177 apical part of cell GO:0098862 cluster of actin-based cell projections

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-549127: Organic cation transport R-HSA-549132: Organic cation/anion/zwitterion transport R-HSA-425407: SLC-mediated transmembrane transport R-HSA-382551: Transmembrane transport of small molecules R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SLC22A5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SLC22A5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SLC22A5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.273	0.254
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.056	0.941
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.427	0.499
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.936	0.033
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.891	0.597
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.995	0.642
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.029	0.909
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.042	0.962
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.03	0.975
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.186	0.889
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.062	0.974
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.112	0.315

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SLC22A5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC22A5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC22A5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC22A5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC22A5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SLC22A5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SLC22A5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SLC22A5
Name	solute carrier family 22 (organic cation/carnitine transporter), member 5
Aliases	OCTN2; CDSP; high-affinity sodium dependent carnitine cotransporter; organic cation/carnitine transporter 2; ......
Chromosomal Location	5q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SLC22A5 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SLC22A5.

ID	Name	Drug Type	Targets	#Targets
DB00583	L-Carnitine	Small Molecule	CES1, CPT1A, CPT2, CRAT, CROT, MPO, SLC22A4, SLC22A5, SLC25A20, SL ......	11

Browse SLC22A5